Threshold Pharmaceuticals Presents Preclinical Results in Two Scientific Presentations at AACR Translational Cancer Medicine Meeting
12 juil. 2010 16h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., July 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug,...
Threshold Pharmaceuticals Initiates a Randomized, Controlled, Phase 2 Clinical Trial Evaluating TH-302 in Patients With Advanced Pancreatic Cancer
30 juin 2010 16h36 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 30, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2...
Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating TH-302 in Patients With Advanced Leukemias
29 juin 2010 08h45 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 29, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with...
Threshold Pharmaceuticals Presents Promising Clinical Trial Results Demonstrating Broad Anti-Tumor Activity
07 juin 2010 09h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced results from Phase 1/2 clinical trials in various solid tumors related to its...
Threshold Pharmaceuticals Announces a Presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting
03 juin 2010 16h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302....
Threshold Pharmaceuticals Appoints Dr. David R. Parkinson to Board of Directors
12 mai 2010 16h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that the Company has appointed Dr. David R. Parkinson to its board of directors....
Threshold Pharmaceuticals Reports First Quarter 2010 Financial and Operational Results
07 mai 2010 08h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 7, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the first quarter ended March 31, 2010.
The net loss for the...
Threshold Announces New Vice President of Corporate Development
06 mai 2010 09h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 6, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced the appointment of Eric Malek as Vice President, Corporate Development. Mr. Malek...
Threshold Pharmaceuticals Presents TH-302 Preclinical Results in Three Scientific Presentations at AACR Annual Meeting
20 avr. 2010 08h35 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 20, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated...
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
04 mars 2010 16h00 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 4, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the fourth quarter and the year ended December 31,...